Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid
- 1 August 2004
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 41 (2), 235-241
- https://doi.org/10.1016/j.jhep.2004.04.010
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Hepatic Stellate Cells as a Target for the Treatment of Liver FibrosisSeminars in Liver Disease, 2001
- After portal branch ligation in the rat, cellular proliferation in associated with selective induction of c-Ha-ras, p53, cyclin E, and Cdk2Gut, 2001
- Disruption of TGF-β growth inhibition by oncogenic ras is linked to p27Kip1 mislocalizationOncogene, 2000
- A mechanism of repression of TGFbeta / Smad signaling by oncogenic RasGenes & Development, 1999
- Tissue inhibitors of metalloproteinases in liver fibrosisThe International Journal of Biochemistry & Cell Biology, 1997
- Activation of ras oncogene in livers with cirrhosisJournal of Hepatology, 1994
- Hemodynamic characterization in experimental liver cirrhosis induced by thioacetamide administrationDigestive Diseases and Sciences, 1993
- The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment StrategiesNew England Journal of Medicine, 1993
- Cellular and molecular aspects of hepatic fibrosisThe Journal of Pathology, 1993
- Ras oncogene mediated induction of a 92kDa metalloproteinase; strong correlation with the malignant phenotypeBiochemical and Biophysical Research Communications, 1988